Published in Medical Patent Week, April 29th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Onyx Pharmaceuticals.
Report 1: Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three months and year ended December 31, 2006. Onyx, with its collaborator, Bayer Pharmaceuticals Corporation, or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer drug currently approved for the treatment of advanced kidney cancer in the U.S., European Union, and other territories internationally. Nexavar net revenue, as recorded by Bayer, was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week